N4 Pharma PLC Result of General Meeting and grant of warrants (4019Q)
18 Junio 2020 - 6:05AM
UK Regulatory
TIDMN4P
RNS Number : 4019Q
N4 Pharma PLC
18 June 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Result of General Meeting and grant of warrants
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that at its general meeting held earlier
today, all resolutions were duly passed. The results of the proxy
voting for the resolutions are set out below.
R esolutio Votes % of Votes % of Total Votes % of
n For* votes Against votes votes withheld** issued
cast** cast** cast** share
capital
voted**
1. To authorise
the Directors
to allot securities. 34,120,538 99.988 4,147 0.0122 34,124,685 0 22.422
2. To disapply
statutory pre-emption
rights***. 34,115,738 99.985 5,200 0.0152 34,120,938 3,747 22.419
----------- -------- --------- -------- ----------- ----------- ---------
*Votes "For" include votes giving the Chairman discretion.
** A 'Vote Withheld' is not a vote in law and has not been
counted in the calculation of the proportion of the votes 'For' and
'Against' a resolution.
*** Proposed as a special resolution.
Following the approval of shareholders at today's general
meeting, and further to the announcement on 1 June 2020, the
Company has now granted warrants over 2,536,562 new ordinary shares
to its brokers in respect of the Placing, as announced on 13 May
2020. The warrants are exercisable at a price of 4p until 20 May
2022.
Following this grant, the Company has a total of 2,536,562
warrants over ordinary shares outstanding, which represents 1.67
per cent. of the Company's issued share capital as at the date of
this announcement.
Defined terms within this announcement shall have the meaning as
set out in the announcement of 1 June 2020 unless otherwise defined
herein.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMFPMBTMTMBBJM
(END) Dow Jones Newswires
June 18, 2020 07:05 ET (11:05 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024